Indiana-based VoCare, Inc. has developed a professional-grade medical diagnostic device that collects six different health vitals and is equipped with WiFi, Bluetooth, and 4G LTE for data transmission, without the need for separate peripherals or an external hub. The Vitals360 device, comparable in size to an iPhone, is the first telehealth solution that can be used for both point-of-care and remote patient monitoring.
The VoCare platform leverages one connected device to facilitate the management of multiple chronic conditions such as diabetes, congestive heart failure, chronic obstructive pulmonary disease, and hypertension. Specifically, the Vitals360 device provides the following vital measurements: blood glucose, blood pressure, pulse, oximetry, temperature, and electrocardiography.
What’s more, the VoCare Vitals360 runs on Android OS powered by Qualcomm chipsets, allowing the device to be used with wireless carriers such as AT&T, Verizon, T-Mobile, Sprint, Rogers, and Vodafone. Moreover, the Vitals360 can be utilized with numerous backend solutions. Steven R. Peabody, CEO of VoCare says: “We are looking forward to helping providers reduce healthcare costs, as well as ensuring better outcomes for their exploding chronically ill patient population.”
Officials for GEMMS, of Harris Computer Systems (a division of Constellation Software, Inc.,), say that the Vitals360 will enable healthcare professionals to meet the requirements of the Centers for Medicare and Medicaid Services Transitional Care and Chronic Care management programs, as well as to be positioned for the use of electronic information and mobile technologies to support remote clinical healthcare and other healthcare delivery functions as proposed in the Chronic Care Act.
Rodger Pinto, PhD, executive vice president of GEMMS says: “The VoCare Vitals360 device, along with GEMMS’ extensive experience in data management and interoperability, will allow patient data to be captured easily from anywhere, at any time and sent in real time to providers.”
VoCare is in the process of obtaining its CE mark and FDA 510k clearance.